Xiaofeng Jia Selected Research

diazonaphthalenedisulfonic acid (NDS)

1/2022	The effect of Glibenclamide on somatosensory evoked potentials after cardiac arrest in rats.
1/2019	Real-time quantitative monitoring of cerebral blood flow by laser speckle contrast imaging after cardiac arrest with targeted temperature management.
10/2015	Early Quantitative Gamma-Band EEG Marker is Associated with Outcomes After Cardiac Arrest and Targeted Temperature Management.
1/2015	Quantitative EEG markers in severe post-resuscitation brain injury with therapeutic hypothermia.
10/2011	Time jitter of somatosensory evoked potentials in recovery from hypoxic-ischemic brain injury.
8/2010	Quantitative assessment of somatosensory-evoked potentials after cardiac arrest in rats: prognostication of functional outcomes.
9/2008	Post-cardiac arrest temperature manipulation alters early EEG bursting in rats.
9/2006	Quantitative EEG and neurological recovery with therapeutic hypothermia after asphyxial cardiac arrest in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaofeng Jia Research Topics

Disease

23	Heart Arrest (Cardiac Arrest) 01/2022 - 01/2006
12	Hypothermia 06/2022 - 09/2006
12	Brain Injuries (Brain Injury) 01/2021 - 01/2008
6	Spinal Cord Injuries (Spinal Cord Injury) 06/2022 - 01/2013
5	Peripheral Nerve Injuries 01/2021 - 01/2018
4	Coma (Comas) 01/2022 - 05/2008
4	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2021 - 07/2021
4	Neoplasms (Cancer) 10/2021 - 12/2020
4	Inflammation (Inflammations) 02/2021 - 06/2012
4	Asphyxia (Suffocation) 07/2019 - 08/2010
4	Neurologic Manifestations (Neurological Manifestations) 01/2019 - 08/2010
3	Neuroinflammatory Diseases 02/2021 - 12/2018
3	Hyperthermia 10/2015 - 06/2008
2	Crush Injuries 01/2021 - 01/2018
2	Out-of-Hospital Cardiac Arrest 01/2021 - 05/2008
2	Stroke (Strokes) 09/2020 - 12/2018
2	Brain Ischemia (Cerebral Ischemia) 01/2020 - 01/2016
2	Wounds and Injuries (Trauma) 01/2013 - 01/2012
2	Hypoxia (Hypoxemia) 01/2013 - 01/2013
1	Muscle Spasticity (Spastic) 02/2022
1	Paralysis (Palsy) 02/2022
1	Leukemia 01/2022
1	Carcinogenesis 10/2021
1	Pain (Aches) 01/2021
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2021
1	Osteosarcoma (Osteogenic Sarcoma) 12/2020
1	Venous Thrombosis (Deep-Vein Thrombosis) 03/2020
1	Ischemic Stroke 01/2020
1	Post-Cardiac Arrest Syndrome 01/2020
1	Hyperalgesia 01/2020
1	Breast Neoplasms (Breast Cancer) 01/2020
1	Neuralgia (Stump Neuralgia) 12/2019
1	Hyperemia 01/2019
1	Edema (Dropsy) 12/2018
1	Cerebral Hemorrhage 12/2018
1	Cicatrix (Scar) 01/2018

Drug/Important Bio-Agent (IBA)

8	diazonaphthalenedisulfonic acid (NDS)IBA 01/2022 - 09/2006
4	Neuroprotective AgentsIBA 01/2022 - 01/2009
4	MicroRNAs (MicroRNA)IBA 12/2021 - 01/2018
4	Proteins (Proteins, Gene)FDA Link 01/2021 - 01/2013
3	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2013
3	HydrogelsIBA 07/2019 - 01/2018
2	Glyburide (Glibenclamide)FDA LinkGeneric 01/2022 - 07/2019
2	Long Noncoding RNAIBA 12/2021 - 07/2021
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2021 - 01/2018
2	Therapeutic UsesIBA 01/2021 - 09/2020
2	salicylhydroxamic acid (SHAM)IBA 01/2020 - 03/2008
2	InflammasomesIBA 07/2019 - 12/2018
2	Poloxamer (Poloxamer 407)IBA 01/2018 - 01/2018
2	Heparin (Liquaemin)FDA LinkGeneric 01/2018 - 01/2018
1	dihydrocapsaicinIBA 06/2022
1	Capsules (Microcapsules)IBA 01/2022
1	arginyl-glycyl-aspartic acidIBA 01/2022
1	Cyclin-Dependent Kinase 6IBA 12/2021
1	Ligases (Synthetase)IBA 12/2021
1	Serine (L-Serine)FDA Link 10/2021
1	Peptide Initiation Factors (Initiation Factor)IBA 10/2021
1	Eukaryotic Initiation Factor-4EIBA 10/2021
1	Biomarkers (Surrogate Marker)IBA 07/2021
1	EnzymesIBA 02/2021
1	sphingosine kinaseIBA 02/2021
1	CytokinesIBA 02/2021
1	SphingosineIBA 02/2021
1	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 02/2021
1	Calcitonin Gene-Related PeptideIBA 01/2021
1	TrehaloseIBA 01/2021
1	Chloroquine (Aralen)FDA LinkGeneric 01/2021
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2021
1	Radiation-Sensitizing AgentsIBA 12/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2020
1	Oxygen (Dioxygen)IBA 01/2020
1	Indicators and Reagents (Reagents)IBA 01/2020
1	Estrogens (Estrogen)FDA Link 01/2020
1	CyclinsIBA 01/2020
1	Phosphotransferases (Kinase)IBA 01/2020
1	Analgesics (Analgesic Drugs)IBA 12/2019
1	PKH 26IBA 07/2019
1	Angiotensin Receptor AntagonistsIBA 12/2018
1	NucleotidesIBA 12/2018
1	Caspase 1 (ICE Protease)IBA 12/2018
1	fimasartanIBA 12/2018
1	Biocompatible Materials (Biomaterials)IBA 01/2018
1	Nerve Growth Factor (NGF)IBA 01/2018
1	Pharmaceutical PreparationsIBA 01/2018
1	Cysteine (L-Cysteine)FDA Link 01/2018
1	Glutamine (L-Glutamine)FDA Link 01/2018
1	Lysine (L-Lysine)FDA Link 01/2018
1	Fibroblast Growth Factor 1 (FGF-1)IBA 01/2018
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 01/2018

Therapy/Procedure

20	Induced Hypothermia 06/2022 - 09/2006
12	Resuscitation 07/2019 - 01/2006
11	Therapeutics 01/2022 - 01/2017
2	Lasers (Laser) 01/2019 - 01/2011
2	Induced Heart Arrest (Cardioplegia) 01/2013 - 08/2010
1	Nerve Transfer 02/2022
1	Drug Therapy (Chemotherapy) 12/2021
1	Radiotherapy 12/2020
1	Replantation 03/2020
1	Spinal Injections 12/2019
1	Injections 12/2019